Some but not all studies have reported reduced rates of stent thrombosis (ST) with everolimus-eluting stents (EES) compared with other drug-eluting stents (DES). All of these studies were insufficiently powered to reliably detect differences in ST. We therefore performed a meta-analysis of randomized controlled trials comparing the risk of 2-year definite ST between EES and other DES.
Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials / Palmerini T; Kirtane AJ; Serruys PW; Smits PC; Kedhi E; Kereiakes D; Sangiorgi D; Reggiani LB; Kaiser C; Kim HS; De Waha A; Ribichini F; Stone GW.. - In: CIRCULATION. CARDIOVASCULAR INTERVENTIONS.. - ISSN 1941-7640. - STAMPA. - 5(3):(2012), pp. 357-364. [10.1161/CIRCINTERVENTIONS.111.967083]
Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
SANGIORGI, DIEGO;BACCHI REGGIANI, MARIA LETIZIA;
2012
Abstract
Some but not all studies have reported reduced rates of stent thrombosis (ST) with everolimus-eluting stents (EES) compared with other drug-eluting stents (DES). All of these studies were insufficiently powered to reliably detect differences in ST. We therefore performed a meta-analysis of randomized controlled trials comparing the risk of 2-year definite ST between EES and other DES.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
